| Name | Title | Contact Details |
|---|
The official Twitter page of Redpoint Cybersecurity
Sagitec is one of the leading providers in Software and Internet. It is based in Saint Paul, MN. To find more information about Sagitec, please visit www.sagitec.com.
PineSpire partners with companies, municipalities, agriculture businesses in earning revenue through Carbon Credit management (LCFS, CFP and CFS). We provide a Tailored Incentive Rates, the PS 2Platform, Detailed Data and Analytics, Comprehensive Fleet...
Fleetmatics is a leading provider of GPS fleet management solutions for business Fleetmatics is a leading global provider of fleet management solutions for small and medium-sized businesses delivered as software-as-a-service (SaaS). Our solutions enable businesses to meet the challenges associated with managing local fleets, and improve the productivity of their mobile workforces, by extracting actionable business intelligence from real-time and historical vehicle and driver behavioral data. Fleetmatics' intuitive, cost-effective Web-based solutions provide fleet operators with visibility into vehicle location, fuel usage, speed and mileage, and other insights into their mobile workforce, enabling them to reduce operating and capital costs, as well as increase revenue. Fleetmatics serves more than 17,000 customers, with over 300,000 actively subscribed vehicles worldwide. Fleetmatics' solutions are marketed and sold under both the Fleetmatics (www.fleetmatics.com) and SageQuest (www.sage-quest.com) brands. The company's North American headquarters are in the Boston area with additional offices in Chicago, Charlotte, Clearwater, Cleveland, and Phoenix, as well as offices in Ireland and the UK.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.